目的 旨在评价现有2型糖尿病临床指南和专家共识,以此为基础了解临床指南和专家共识之间的差距,对专家共识的制定提出建议。方法 系统检索PubMed、Embase、中国知网(CNKI)、万方数据知识服务平台、中国生物医学文献服务系统(SinoMed)等数据库。根据纳入排除标准筛选国内外关于2型糖尿病药物治疗的指南和共识。采用AGREE Ⅱ评估工具评价指南和共识的方法学质量。结果 纳入的指南间质量有一定差距,但整体质量仍远高于共识。指南在范围和目的、清晰性两个领域得分较高,在严谨性和应用性领域得分较低。共识在6个领域的得分均较低。结论 造成指南和共识间差异的主要原因是共识在方法学上存在较大缺陷,因此本研究推荐使用快速建议指南代替共识。
Abstract
OBJECTIVE To evaluate the quality of now available clinical guidelines and consensus statements on type 2 diabetes. Based on this assessment, the comparison of guidelines and consensuses is made to give some suggestions on the METHODS of making these documents. METHODS PubMed, Embase, CNKI, Wanfang, SinoMed and guideline websites were systematically searched. Literatures were screened according to defined criteria for including. AGREE Ⅱ was used to instrument assess the quality of the guidelines and consensuses. RESULTS The result showed that the quality of included guidelines is various, but the overall quality of guidelines is still higher than consensuses. Guidelines got high scores in scope and purpose domain and clarity of presentation domain, but low scores in rigor of development domain and applicability domain. Consensus statements got low scores in all 6 domains. CONCLUSION The main reason for the difference is consensuses have poor methodology. Rapid advice guidelines were suggested as an alternative for consensus statements.
关键词
2型糖尿病 /
指南 /
快速建议指南 /
专家共识 /
AGREE Ⅱ
{{custom_keyword}} /
Key words
type 2 diabetes /
guideline /
rapid advice guideline /
consensus statement /
AGREE Ⅱ
{{custom_keyword}} /
中图分类号：
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SUN Z X, LIU N F. The guiding role of clinical practice guidelines in good evidence-based clinical pharmacy practice [J]. Chin Pharm J(中国药学杂志),2014,49(21):1950-1956.
[2] AGREE COLLABORATION. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines:the AGREE project, Qual. Saf[J]. Health Care,2003,12(1):18-23.
[3] AMERICAN DIABETES ASSOCIATION. Standards of medical care in diabetes 2015[J]. Diabetes Care,2015,38(suppl):4.
[4] HANDELSMAN Y, BLOOMGARDEN Z T, GRUNBERGER G, et al. American association of clinical endocrinologists and american college of endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015[J]. Endocr Pract, 2015,21(suppl 1):187.
[5] NATIONAL INSTITUTE FOR HEALTH AND CARE EXCEL-LENCE. Type 2 diabetes:The management of type 2 diabetes[EB/OL]. London (UK):National Institute for Health and Clinical Excellence,2009(Updated in 2014),[2015-11-02]. https://www.nice.org.uk/guidance/cg87
[6] INTERNATIONAL DIABETES FEDERATION GUIDELINE DEVELOPMENT GROUP.Global guideline for type 2 diabetes[J]. Diabetes Res Clin Pract, 2014,104(1):152.
[7] INTERNATIONAL DIABETES FEDERATION GUIDELINE DEVELOPMENT GROUP. Guideline for management of postmeal glucose in diabetes[J]. Diabetes Res Clin Pract, 2014, 103(2):256-268.
[8] GOH S Y, ANG S B, BEE Y M, et al. Ministry of health clinical practice guidelines:diabetes mellitus[J]. Singapore Med J, 2014,55(6):334-347.
[9] NATIONAL INSTITUTE FOR HEALTH AND CARE EXCEL-LENCE.Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes [EB/OL]. London (UK):National Institute for Health and Clinical Excellence,2012(Updated in 2014), [2015-11-02]. https://www.nice.org.uk/guidance/ta248.
[10] NATIONAL INSTITUTE FOR HEALTH AND CARE EXCEL-LENCE. Dapagliflozin in combination therapy for treating type 2 diabetes[EB/OL]. London (UK):National Institute for Health and Clinical Excellence,2013[2015-11-02]. https://www.nice.org.uk/guidance/ta288.
[11] UNVIVERSITY OF MICHIGAN HEALTH SYSTEM. Management of Diabetes Mellitus [EB/OL]. Michigan(USA):Unviversity of Michigan Health System,2014[2015-11-02].http://www.med.umich.edu/index.html
[12] INSTITUTE FOR CLINICAL SYSTEMS IMPROVEMENT. Diagnosis and Management of Type 2 Diabetes Mellitus in Adults [EB/OL]. Bloomington (MN):Institute for Clinical Systems Improvement,2014[2015-11-02]. http://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_endocrine_guidelines/diabetes/
[13] PETER J G, STEFAN D A, CHRISTIAN B,et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J, 2013,34(39):3035-3087.
[14] COPELAND K C, SILVERSTEIN J, MOORE K R, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents [J]. Pediatrics, 2013, 131(2):364-382.
[15] CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. Optimal Use Recommendations for Second-and Third-Line Therapy for Patients With Type 2 Diabetes [EB/OL]. Ottawa (ON). Canadian Agency for Drugs and Technologies in Health,2013[2015-11-02]. https://www.cadth.ca/second-third-line-therapies-type-2-diabetes
[16] CHINESE DIABETES SOCIETY.Chinese type 2 diabetes prevention and therapy guideline [J].Chin J Diabetes(中国糖尿病杂志),2014,8:242.
[17] QASEEM A, HUMPHREY L L, SWEET D E, et al. Oral pharmacologic treatment of type 2 diabetes mellitus:a clinical practice guideline from the American College of Physicians [J]. Ann Intern Med, 2012,156(3):218-231.
[18] KO S H, KIM S R, KIM D J, et al. 2011 Clinical practice guidelines for type 2 diabetes in Korea [J]. Diabetes Metab J, 2011,35(5):431-436.
[19] SCOTTISH INTERCOLLEGIATE GUIDELINES NETWORK. Management of diabetes[EB/OL]. Edinburgh (Scotland):Scottish Intercollegiate Guidelines Network, 2010(Updatedin 2014)[2015-11-02]. http://www.sign.ac.uk/guidelines/fulltext/116/index.html
[20] THE DEPARTMENT OF VETERANS AFFAIRS AND THE DEPARTMENT OF DEFENSE.(2010) VA/DoD clinical practice guideline for the management of diabetes mellitus[EB/OL]. NW Washington DC (USA):The Department of Veterans Affairs and The Department of Defense, 2010[2015-11-02]. http://www.healthquality.va.gov/guidelines/CD/diabetes/
[21] GARBER A J, ABRAHAMSON M J, BARZILAY J I, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement[J]. Endocr Pract,2013,19(3):536-557.
[22] KIRKMAN M S, BRISCOE V J, CLARK N, et al. Diabetes in older adults:a consensus report [J]. J Am Geriatr Soc,2012,60(12):2342-2356.
[23] MENENDEZ T E, LAFITA T J, ARTOLA M S, et al. Recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes[J]. Consensus Document Nefrologia,2011,31(1):17-26.
[24] WOO J T, PARK K S, BYUN D W, et al. Regulation of glucose control in people with type 2 diabetes:a review and consensus[J]. Korean Diabetes J,2010,34(1):16-20.
[25] GUZMAN J R, LYRA R, AGUILAR-SALINAS C A, et al. Treatment of type 2 diabetes in Latin America:a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association[J]. Rev Panam Salud Publica,2010,28(6):463-471.
[26] RAMSAY S, WALKER J D, JAPP A. Achieving consensus on current diabetes issues[J]. Br J Diabe Vascul Dis,2010,10(4):157-160.
[27] CHINESE DIABETES SOCIETY. Clinical practice consensus on GLP-1 receptor agonist drugs [J]. Chin J Diabetes(中国糖尿病杂志),2014,6(1):1420.
[28] CHINESE SOCIETY OF ENDOCRINOLOGY. Chinese consensus on insulin use in type 2 diabetes in adults[J]. Chin J Endocrinol Metab(中华内分泌代谢杂志),2013,29(1):16.
[29] CHINA ASSOCIATION OF GERONTOLOGY AND GERIATRICS. Consensus on diagnosis and therapy of diabetes in old people [J]. Chin J Intern Med(中华内科杂志), 2014, 53(3):243-251.
[30] CHINESE DIABETES SOCIETY. Consensus on insulin short term therapy of newly diagnosed type 2 diabetes [J]. Natl Med J China(中华医学杂志), 2013,93(20):1524-1526.
[31] CHINESE SOCIETY OF ENDOCRINOLOGY. Chinese consensus on the use of insulin secretagogue in adult type 2 diabetes [J]. Chin J Endocrinol Metab(中华内分泌代谢杂志),2012,28(4):261-265.
[32] CHINESE PEDIATRIC SOCIETY. Guidelines on insulin therapy in children and adolescent [J]. Chin J Pediatr(中华儿科杂志), 2010,48(6):431-435.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(646 KB)
